Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.35 |
| ▸ | DPP4 | P27487 | 4/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.35 |
| ▸ | NOS1 | P29475 | 3/20 | 0.33 |
| ▸ | NOS2 | P35228 | 3/20 | 0.33 |
| ▸ | GRB2 | P62993 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 4/20 | 0.32 |
| ▸ | GABRD | O14764 | 4/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.32 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.32 |
| ▸ | GABRE | P78334 | 4/20 | 0.32 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4093984 | 1.00 | SLC7A5 (0.36) | SLC7A5DPP7DPP4DPP8NOS1 | |
| Trifluoroacetic Acid SCHEMBL5048203 | 1.00 | SLC7A5 (0.36) | SLC7A5DPP7DPP4DPP8NOS1 | |
| Trifluoroacetic Acid SCHEMBL29880406 | 1.00 | SLC7A5 (0.36) | SLC7A5DPP7DPP4DPP8NOS1 | |
| Trifluoroacetic Acid SCHEMBL7439665 | 0.86 | SLC7A5 (0.43) | SLC7A5DPP7DPP4DPP8GRB2 | |
| Trifluoroacetic Acid SCHEMBL29441736 | 0.86 | SLC7A5 (0.43) | SLC7A5DPP7DPP4DPP8GRB2 | |
| Trifluoroacetic Acid SCHEMBL7449149 | 0.86 | NOS1 (0.34) | SLC7A5DPP7DPP4DPP8NOS1 | |
| Trifluoroacetic Acid SCHEMBL6104013 | 0.86 | SLC7A5 (0.43) | SLC7A5DPP7DPP4DPP8GRB2 | |
| Trifluoroacetic Acid SCHEMBL7444190 | 0.86 | NOS1 (0.34) | SLC7A5DPP7DPP4DPP8NOS1 | |
| Trifluoroacetic Acid SCHEMBL3416090 | 0.86 | SLC7A5 (0.41) | SLC7A5DPP7DPP4DPP8GRB2 | |
| Trifluoroacetic Acid SCHEMBL7720576 | 0.84 | NOS1 (0.33) | SLC7A5DPP7DPP4DPP8NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299263-A1 | Hydroxy Alkyl Amines | Elan Pharmaceuticals, Inc. and Pharmacia & Upjohn Company | 2007-12-27 | — | — | US | claimed |
| EP-1254136-A4 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD (KR) | 2005-06-01 | — | — | EP | claimed |
| EP-1453789-A2 | N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| EP-1395551-A2 | HYDROXY ALKYL AMINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND THEIR USE FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND SIMILAR DISEASES | Elan Pharmaceuticals, Inc. (US) | 2004-03-10 | — | — | EP | claimed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | claimed |
| WO-2002098849-A2 | HYDROXY ALKYL AMINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND THEIR USE FOR THE TREATMENT OF ALZHEIMER’S DISEASE AND SIMILAR DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | claimed |
| EP-1254136-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG Chem Investment, Ltd. (KR) | 2002-11-06 | — | — | EP | claimed |
| WO-2001055146-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD. (KR) | 2001-08-02 | — | — | WO | claimed |
| US-20240026030-A1 | METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-01-25 | — | — | US | disclosed |
| EP-3049403-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2016-08-03 | — | — | EP | disclosed |
| WO-2015044172-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-02 | — | — | WO | disclosed |
| WO-2012143499-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-08-13 | — | — | US | disclosed |
| US-7368424-B2 | Acylated nonadepsipeptides | AICURIS GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
| WO-2006127458-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-30 | — | — | WO | disclosed |
| EP-1254136-A4 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD (KR) | 2005-06-01 | — | — | EP | disclosed |
| EP-1395551-A2 | HYDROXY ALKYL AMINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND THEIR USE FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND SIMILAR DISEASES | Elan Pharmaceuticals, Inc. (US) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002098849-A2 | HYDROXY ALKYL AMINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND THEIR USE FOR THE TREATMENT OF ALZHEIMER’S DISEASE AND SIMILAR DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
| EP-1254136-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG Chem Investment, Ltd. (KR) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055146-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD. (KR) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240026030-A1 | METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE | ERBB2, EGFR, H1-2 | SLC7A5 1123/4885DPP7 2910/4885DPP4 3766/4885 |
| US-20070299263-A1 | Hydroxy Alkyl Amines | MAOA, PSEN2, PSEN1 | SLC7A5 466/4885DPP7 4726/4885DPP4 4694/4885 |
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | HIPK3, HIPK1, HIPK4 | SLC7A5 3528/4885DPP7 2204/4885DPP4 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.